BCL2 and benign prostatic hyperplasia: Further, the ratio of Bcl-2 to Bax significantly (p < 0.001) decreased in both the Fina and SC 50 groups, compared with the BPH group, where the ratio of Bcl-2 to Bax markedly increased compared to the control group (Fig 5D).